Multifunctional molecules targeting CD24
Multispecific antibodies targeting CD24 and immune checkpoint proteins improve cancer treatment and immune response by enhancing phagocytosis and modulating immune pathways.
WO2025218729A1 Publication Date: 2025-10-23I MAB BIOPHARMA CO LTD
7 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2025/089494
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-17
- Filing Date
- 2025-04-17
- Publication Date
- 2025-10-23
AI Technical Summary
Technical Problem
Current therapies lack effective multispecific antibodies targeting CD24 and immune checkpoint proteins for treating cancers and infectious diseases.
Method used
Development of multispecific antibodies comprising a CD24 binding moiety and a second antigen-binding moiety that targets immune checkpoint proteins, such as PD-L1 or CD47, to enhance immune response against cancer cells and infectious agents.
Benefits of technology
Enhances phagocytosis of cancer cells by macrophages and modulates immune checkpoint pathways, leading to improved cancer treatment and immune response against infections.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided are multispecific antibodies or fragments thereof having binding specificity to the human CD24 protein. Methods of using the antibodies or fragments thereof for treating cancer, autoimmune disease or inflammatory condition are also provided.
Need to check novelty before this filing date? Find Prior Art